CervoMed Inc. (CRVO)

CervoMed Inc. is trading at $2.58, down 1.90% on the session. The 50 day average sits at $3.01 and the 200 day at $4.77, which puts the stock in a downtrend. RSI is at 42.2, which reads as weak, and MACD is bullish crossover. Volume is below average.

The nearest support is around $2.50 with resistance near $2.73, so that band frames the current range. Average daily movement is roughly $0.20, or about 7.7% of the share price, which is what any stop placement has to allow for. The overall health score of 30 out of 100 combines a trend score of 3, momentum of 59 and a risk score of 34.

CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule drug that crosses the blood–brain barrier and inhibits the enzyme p38a. Neflamapimod has the potential to reverse synaptic dysfunction, improve neuron health, and slow or prevent disease progression. Neflamapimod is currently in clinical development for the treatment of dementia with Lewy bodies, non-fluent variant primary progressive aphasia, amyotrophic lateral sclerosis, and amyotrophic lateral sclerosis. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.